#### Over 90% of rare diseases have no treatment...

- There are more than 6,000 known rare diseases...
- Approximately 80% of them have a genetic component... 75% affect children...
- And most rare diseases are chronic conditions, many of which progress overtime and are potentially fatal...

Understanding the rare disease framework is key to be able to offer study participants adapted solutions and as such, positively contribute to important and necessary clinical research conducted on rare diseases.

Kayentis offers an extensive experience in rare disease clinical trials, in indications such as:

- Prader-Willi Syndrome
- PIK3CA-related overgrowth spectrum
  - Auto-Immune Hepatitis (AIH)
    - Hypoparathyroidism
    - Sjögren's syndrome
      - Acute Vertigo

## RARE DISEASE CASE STUDY

# Kayentis offers an extensive experience in rare disease clinical trials

# IN INDICATIONS SUCH AS:

- PIK3CA-related overgrowth spectrum
- Auto-Immune Hepatitis (AIH)
- Hypoparathyroidism
- Sjögren's syndrome

### **UP TO 38 COUNTRIES**

AROUND 2,500 PATIENTS ABOUT 1,000 SITES ACROSS THE GLOBE: Europe – US – Asia – Oceania

#### ASSESSMENTS

- PROs: Appetite NRS, EQ-5D-5L SELF, Vertigo Intensity, DSS-SF, Nausea Severity, DHI, Vestibular Disorders Activities of Daily Living Scale - PROMIS Fatigue, SF 13A, SF-12, Injection-Site Reaction Questionnaire
- Pediatric PROs: PedsQL™ Young Adult (ages 18-25), PedsQL™ Pediatric (ages 12-18)
- ObsROs: EQ-5D-5L PROXY,PedsQL™ Adult, HQ-CT, CgGIS-H, CgGIC-H, Zarit Burden
- eDiary: Vestibular Disorders Activities of Daily Living Scale eDiary for drug intake (IMP daily injection compliance/ Site injection/ Calcium and Vit D supplements intake count/ other treatment intake - Sjögren syndrome patient diary - SSSD
- ClinROs: PhGA / ESSDAI / CDAI


Download the case study Contact us for more information

#### **Key Words:**

eCOA

- ePRO
- eDiary
- rare disease
- clinical trial

#### **Learn more:**



Rethinking pediatric clinical trials: guidelines from pediatric experts 2 April 2024

In this last episode on pediatric clinical trial challenges, Begoña Nafria, pediatrician and patient engagement



# Overcoming challenges in long-lasting pediatric clinical trials – Insights from site experts

26 March 2024

In this third episode on pediatric clinical trial challenges, Begoña Nafria, pediatrician and patient engagement

Read More »



Tackling the specificities of NASH/MASH clinical trials 26 March 2024

Integrating PROs into studies on MASH, also known as NASH, is crucial. MASH is a debilitating



Mastering pediatric asthma clinical trials

19 March 2024

Asthma clinical trials present several specificities, such as the use of disease-specific health-related quality of




The importance of ePRO to support NASH/NAFLD unmet clinical

#### research and medical needs

14 March 2024

NonAlcoholic SteatoHepatitis (NASH), now called Metabolic Dysfunction-Associated SteatoHepatitis (MASH), affects almost 115 million adults globally

Read More »



**How DCTs Can Help Pediatric Clinical Research – Insights From Site Experts** 

12 March 2024

In this second episode on pediatric clinical trial challenges, Begoña Nafria, pediatrician and patient engagement